Blog of the Society for Menstrual Cycle Research
Here’s an interesting political approach. While there are hairs to split (do all women have vaginas? do all people with vaginas consider themselves women? and what about those of us with no sexual partners, or sexual partners without penises?), there’s something to be said for appealing to the majority. After all, those of us who already get it, get it, no?
I do wish it came with an action plan, though. Links to a site for people to contact their congresscritters would be good.
I’m too swamped at work to write a proper review of this book-length report this week, but re:Cycling readers might like to know that the Board on Population Health and Public Health Practice (BPH) and the Institute of Medicine (IOM) are releasing a pre-publication version of Women’s Health Research: Progress, Pitfalls, and Promise. You can read it online, and/or order the final version here.
[via Our Bodies, Our Blog]
Longtime readers may recall that late last year, the New York Times published an essay about how hard Big Pharma has worked to market menopause as an estrogen deficiency disease. Despite that exposé and others of the well-documented risks and limited benefits of hormone therapy, plus thousands of lawsuits pending over the role of HT in breast cancer, there’s apparently still quite a large potential market for pharmaceutical treatments for menopause (and other women’s health concerns).
To find out exactly how to mine that market, you can purchase the research report titled Women’s Health Therapeutics Market to 2016 – High Unmet Need will Drive the Uptake of Novel Drugs in Menopause and Osteoporosis from GBI Research. The report promises the following:
- Analysis of the women’s health market in the leading geographies of the world, which include the US, the UK, Germany, France, Italy, Spain and Japan.
- Market characterization of the women’s health market, including market size, annual cost of therapy, sales volume and treatment usage patterns.
- Key drivers and barriers that have a significant impact on the market.
This will better allow you to “align your product portfolio to the markets with high growth potential” and “develop market-entry and market expansion strategies by identifying the leading therapeutic segments and geographic markets poised for strong growth”. Not to mention the ability to “reinforce R&D pipelines by identifying new target mechanisms which can produce first-in-class molecules with more efficiency and better safety”.
It all looks very useful. Too bad I don’t have an extra $3500 in my back pocket.
